SUPN — Supernus Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.80bn
- $1.34bn
- $661.82m
- 100
- 62
- 90
- 98
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.93 | ||
| PEG Ratio (f) | 0.59 | ||
| EPS Growth (f) | 33.9% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.73 | ||
| Price to Tang. Book | 4.53 | ||
| Price to Free Cashflow | 10.49 | ||
| Price to Sales | 2.71 | ||
| EV to EBITDA | 8.28 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.59% | ||
| Return on Equity | 7.55% | ||
| Operating Margin | 12.34% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 520.4 | 579.77 | 667.24 | 607.52 | 661.82 | 624.69 | 681.82 | 11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +18.16 | -48.34 | -18.75 | -81.13 | +632.58 | +37.5 | +28.28 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
Directors
- Charles Newhall CHM (76)
- Jack Khattar PRE (59)
- Timothy Dec CFO (62)
- Padmanabh Bhatt SVP (63)
- Tami Martin SVP (65)
- Frank Mottola SVP (49)
- Jonathan Rubin SVP (59)
- Carrolee Barlow IND (57)
- Frederick Hudson IND (75)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 30th, 2005
- Public Since
- December 28th, 2010
- No. of Shareholders
- 15
- No. of Employees
- 674
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 55,743,095
- Address
- 9715 Key West Avenue, ROCKVILLE, 20850
- Web
- https://www.supernus.com
- Phone
- +1 3018382500
- Contact
- Peter Vozzo
- Auditors
- KPMG LLP
Upcoming Events for SUPN
Q1 2025 Supernus Pharmaceuticals Inc Earnings Call
Supernus Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Supernus Pharmaceuticals Inc Earnings Release
Similar to SUPN
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Supernus Pharmaceuticals share price?
As of Today at 23:31 UTC, shares in Supernus Pharmaceuticals are trading at $32.22. This share price information is delayed by 15 minutes.
How has the Supernus Pharmaceuticals share price performed this year?
Shares in Supernus Pharmaceuticals last closed at $32.22 and the price had moved by +9.93% over the past 365 days. In terms of relative price strength the Supernus Pharmaceuticals share price has outperformed the S&P500 Index by +1.47% over the past year.
What are the analyst and broker recommendations for Supernus Pharmaceuticals?
The overall consensus recommendation for Supernus Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Supernus Pharmaceuticals dividend yield?
Supernus Pharmaceuticals does not currently pay a dividend.
Does Supernus Pharmaceuticals pay a dividend?
Supernus Pharmaceuticals does not currently pay a dividend.
When does Supernus Pharmaceuticals next pay dividends?
Supernus Pharmaceuticals does not currently pay a dividend.
How do I buy Supernus Pharmaceuticals shares?
To buy shares in Supernus Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Supernus Pharmaceuticals?
As of the previous close price of $32.22, shares in Supernus Pharmaceuticals had a market capitalisation of $1.80bn.
Where are Supernus Pharmaceuticals shares listed?
Here are the trading details for Supernus Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SUPN
What kind of share is Supernus Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Supernus Pharmaceuticals is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Supernus Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Supernus Pharmaceuticals is $38.80. That is 20.42% above the last closing price of $32.22.
Analysts covering Supernus Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $1.98 for the next financial year.
Find out moreWhat is the trend in the Supernus Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Supernus Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +0.09%.
As of the last closing price of $32.22, shares in Supernus Pharmaceuticals were trading -5.05% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Supernus Pharmaceuticals PE Ratio?
The Supernus Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 14.93. The shares last closed at $32.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Supernus Pharmaceuticals?
Supernus Pharmaceuticals' management team is headed by:
- Charles Newhall - CHM
- Jack Khattar - PRE
- Timothy Dec - CFO
- Padmanabh Bhatt - SVP
- Tami Martin - SVP
- Frank Mottola - SVP
- Jonathan Rubin - SVP
- Carrolee Barlow - IND
- Frederick Hudson - IND